Christopher Chen

Christopher Chen of Baird asked about the operational synergies between the GAD and MDD trials, specifically patient crossover during screening, and requested details on the in-clinic treatment protocol, including provider roles and the distinction from psychotherapy.

Answer

CEO Robert Barrow confirmed that the trials were designed for screening efficiency, allowing patients who screen for GAD but have MDD to easily move into the depression program. Chief Medical Officer Dr. Daniel Karlin clarified that a provider is present to monitor the patient, but training is explicit that their role is assistance, not psychotherapy, with the focus on patient safety.

Christopher Chen from Baird asked to confirm the operational synergy of enrolling patients screened for GAD into the MDD trial if applicable, and requested more detail on the treatment visit, including provider presence and guardrails against psychotherapy.

Answer

CEO Robert Barrow confirmed the trial design allows for efficient crossover from GAD screening to MDD enrollment. CMO Dr. Daniel Karlin explained that during the treatment visit, a provider is present for monitoring and assistance, with explicit training and protocols in place to ensure they do not engage in psychotherapy while the patient focuses on their internal experience.